Metvix (Methyl Aminolevulinate)

Methyl aminolevulinate is a prodrug that is taken up by skin cells and converted into protoporphyrin IX. When the area is illuminated with a specific light wavelength, the protoporphyrin IX generates reactive oxygen species that selectively destroy abnormal keratinocytes while sparing normal tissue.

The prescribed amount of Metvix is determined by the treating physician based on the size and number of lesions. The clinician decides the exact quantity to apply, the incubation time before illumination, and the light dose required for each patient.

The safety of Metvix in pregnancy and lactation has not been established. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Metvix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metvix offers a targeted photodynamic approach that can treat multiple lesions in a single session, whereas alternatives such as cryotherapy, topical 5‑fluorouracil or imiquimod rely on chemical or physical destruction. Photodynamic therapy may provide better cosmetic outcomes and lower recurrence rates for extensive field cancerization.

Metvix should be stored at room temperature, below 25 °C, in its original packaging. Keep the cream away from direct sunlight, excessive heat and moisture to maintain its stability and potency.

Metvix is applied topically to the affected skin area by a healthcare professional. After a defined incubation period, the treated skin is illuminated with a specific light source to activate the photosensitizer, completing the photodynamic therapy session.

The most serious risks include severe phototoxic reactions leading to extensive skin damage, secondary infections of the treated area, and rare allergic or systemic hypersensitivity responses. Patients should be monitored closely and instructed to avoid intense light exposure after treatment.

Metvix should not be used in individuals with known porphyria, hypersensitivity to methyl aminolevulinate or any component of the cream, or in patients who cannot avoid post‑treatment light exposure as instructed by their clinician.